Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (151-160 of 200) with videos related to

Pageof 20
Sort By:
Pneumologie (Stuttgart, Germany)|March 1, 2023
[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]Jürgen Behr, Francesco Bonella, Björn C Frye, et al.
Chest|April 28, 2009
Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluationRobert P Baughman, Ralph Shipley, Sujal Desai, et al.
Pneumologie (Stuttgart, Germany)|February 15, 2023
[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]Jürgen Behr, Francesco Bonella, Björn C Frye, et al.
Respiration; International Review of Thoracic Diseases|September 9, 2024
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses: S2k Guideline of the German Respiratory SocietyJürgen Behr, Francesco Bonella, Björn Christian Frye, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2010
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Pneumologie (Stuttgart, Germany)|September 3, 2024
[Diagnosis and Treatment of Hypersensitivity Pneumonitis - S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology]Dirk Koschel, Jürgen Behr, Melanie Berger, et al.
Respiration; International Review of Thoracic Diseases|January 27, 2025
Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical ImmunologyD Koschel, J Behr, M Berger, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 9, 2016
MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?Christian Mölleken, Gereon Poschmann, Francesco Bonella, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2011
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Advances in Therapy|March 19, 2014
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse eventsUlrich Costabel, Elisabeth Bendstrup, Vincent Cottin, et al.
Pageof 20

Showing results (151-160 of 200) with videos related to

Sort By:
Pageof 20
Pneumologie (Stuttgart, Germany)|March 1, 2023
[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]Jürgen Behr, Francesco Bonella, Björn C Frye, et al.
Chest|April 28, 2009
Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluationRobert P Baughman, Ralph Shipley, Sujal Desai, et al.
Pneumologie (Stuttgart, Germany)|February 15, 2023
[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]Jürgen Behr, Francesco Bonella, Björn C Frye, et al.
Respiration; International Review of Thoracic Diseases|September 9, 2024
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses: S2k Guideline of the German Respiratory SocietyJürgen Behr, Francesco Bonella, Björn Christian Frye, et al.
American Journal of Respiratory and Critical Care Medicine|December 7, 2010
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Pneumologie (Stuttgart, Germany)|September 3, 2024
[Diagnosis and Treatment of Hypersensitivity Pneumonitis - S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology]Dirk Koschel, Jürgen Behr, Melanie Berger, et al.
Respiration; International Review of Thoracic Diseases|January 27, 2025
Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical ImmunologyD Koschel, J Behr, M Berger, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 9, 2016
MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?Christian Mölleken, Gereon Poschmann, Francesco Bonella, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2011
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important differenceRoland M du Bois, Derek Weycker, Carlo Albera, et al.
Advances in Therapy|March 19, 2014
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse eventsUlrich Costabel, Elisabeth Bendstrup, Vincent Cottin, et al.
Pageof 20